Lupus is treated with a combination of medications tailored to the severity of the disease and which organs are affected. Nearly every person with systemic lupus erythematosus (SLE) takes an antimalarial drug called hydroxychloroquine as a baseline, with additional medications layered on depending on whether the disease is mild, moderate, or severe. There is no single pill that treats all forms of lupus, but the options available today can bring more than 70% of patients into prolonged remission.
Hydroxychloroquine: The Foundation of Lupus Treatment
Hydroxychloroquine is the cornerstone medication for lupus. Originally developed to treat malaria, it works by calming the overactive immune system that drives lupus symptoms. It reduces flares, protects organs from long-term damage, and is typically taken for years or even indefinitely. In a long-term cohort study, 72% of patients on a stable daily dose achieved prolonged remission. The standard dose is 200 mg per day, though your doctor may adjust it based on your body weight.
Because hydroxychloroquine is used long-term, eye health is a real consideration. The drug can, in rare cases, damage the retina. For patients taking a properly adjusted dose, the likelihood of this toxicity is below 1% within the first five years and stays below 2% even after ten years. The American Academy of Ophthalmology recommends annual eye screenings, which can be deferred during the first five years if you have no major risk factors. After that, yearly screening is important to catch any changes early.
Anti-Inflammatory Pain Relief
Up to 80% of people with lupus use nonsteroidal anti-inflammatory drugs (NSAIDs) like ibuprofen or naproxen for joint pain, chest inflammation from pleurisy, and headaches. These are often the first thing people reach for because they’re accessible and effective for day-to-day discomfort. However, NSAIDs require more caution in lupus than in the general population. People with lupus are more prone to kidney side effects from these drugs, and those with lupus nephritis face a higher risk of acute kidney injury. Skin reactions and liver effects (particularly with high-dose aspirin) also occur more frequently. NSAIDs work well for symptom relief but don’t treat the underlying disease.
Corticosteroids for Flares
When lupus flares up, corticosteroids like prednisone are the fastest way to bring inflammation under control. How they’re used depends entirely on the severity of the flare.
For mild flares involving joint pain or limited skin rashes, a low dose of prednisone (2.5 to 7.5 mg per day) tapered over one to two weeks is often enough. Moderate flares, such as widespread skin involvement or significant drops in blood cell counts, typically call for a short course of intravenous steroids for three days followed by oral prednisone at 5 to 20 mg per day, tapered down to 5 mg or less over two to four weeks. Severe flares affecting the kidneys, lungs, or brain may start with higher intravenous doses for three days, then oral prednisone starting at a maximum of 30 mg per day, stepped down every two weeks until reaching 5 mg per day.
The goal in modern lupus care is to keep long-term steroid doses as low as possible, ideally at or below 5 mg per day. Research consistently shows that doses above 30 mg per day increase toxicity without adding meaningful benefit. Prolonged steroid use carries serious consequences: patients on chronic steroids have significantly higher rates of cardiovascular disease (46% compared to 30% in those not taking steroids), more than double the rate of osteoporosis, and increased risks of diabetes, cataracts, and bone fractures. Some of this damage is irreversible, which is why doctors work to taper steroids quickly and rely on other medications for long-term control.
Immunosuppressants for Organ Involvement
When lupus threatens major organs, particularly the kidneys, immunosuppressant drugs become essential. These medications broadly suppress immune activity to prevent the body from attacking its own tissues.
Mycophenolate is one of the most commonly used options, especially for lupus nephritis (kidney involvement). In a major trial published in the New England Journal of Medicine, mycophenolate proved significantly better than azathioprine at maintaining kidney function after initial treatment. Only 16.4% of patients on mycophenolate experienced treatment failure over 36 months, compared to 32.4% on azathioprine. Mycophenolate also reduced the risk of kidney flares and the need for rescue therapy.
Azathioprine remains a useful alternative, particularly for patients who can’t tolerate mycophenolate or who are planning pregnancy (mycophenolate causes birth defects). Both drugs require regular blood work to monitor blood cell counts and organ function.
Current guidelines from the American College of Rheumatology recommend that lupus nephritis treatment should be thought of as continuous rather than divided into separate “induction” and “maintenance” phases. Patients who achieve complete kidney response typically stay on immunosuppressive therapy for three to five years.
Biologic Therapies
Two biologic medications are currently approved for lupus, and they represent the newest class of treatment. Unlike broad immunosuppressants, biologics target specific parts of the immune system.
Belimumab (Benlysta) works by blocking a protein that helps certain immune cells survive. It’s been shown across five randomized trials to reduce disease activity, lower steroid needs, and decrease the frequency of flares. It can be given as an intravenous infusion or a self-administered injection under the skin.
Anifrolumab (Saphnelo) targets a different pathway, blocking the signaling of type I interferons, which are overactive in many lupus patients. Its approval was based on favorable results in two of three clinical trials. When researchers compared the two biologics indirectly across eight clinical trials, belimumab and anifrolumab showed comparable overall effectiveness, with response rates that were statistically similar. Neither has proven clearly superior to the other, and the choice between them often depends on which aspects of the disease are most active.
Biologics are typically added on top of hydroxychloroquine and other medications rather than used alone. They’re most often considered when the disease remains active despite standard treatment.
Specialized Treatment for Lupus Nephritis
Kidney involvement affects a significant portion of lupus patients and requires its own treatment approach. In addition to mycophenolate and steroids, a newer medication called voclosporin (Lupkynis) is FDA-approved specifically for active lupus nephritis. It works by suppressing a specific enzyme in immune cells and is used alongside mycophenolate and corticosteroids.
In its pivotal trial, 40.8% of patients on voclosporin achieved complete kidney response at one year, compared to 22.5% on placebo. Patients on voclosporin also saw their kidney protein levels normalize roughly twice as fast, with a median time of 169 days versus 372 days. Kidney function is monitored closely during treatment, and the medication is discontinued if there’s no benefit by 24 weeks or if kidney filtration drops significantly.
Topical Treatments for Skin Lupus
Lupus skin rashes, including the butterfly-shaped facial rash and disc-shaped lesions (discoid lupus), can be treated with creams and ointments applied directly to the skin. Steroid creams are the traditional first choice, but topical calcineurin inhibitors like tacrolimus ointment offer an effective alternative, especially on the face where long-term steroid creams can thin the skin.
In a systematic review, all patients receiving tacrolimus or pimecrolimus experienced improvement in redness, scaling, and swelling. Higher-strength tacrolimus (0.1%) works better than lower concentrations. Facial lesions in patients with resistant discoid lupus nearly completely disappeared after six to eight weeks of tacrolimus treatment. Combining a topical treatment with hydroxychloroquine produced even better results: 100% of patients on combination therapy saw improvement in swelling, compared to 75% on the topical alone. For patients with scarring hair loss from discoid lupus, tacrolimus ointment combined with an antimalarial has shown hair regrowth in small studies.
How These Medications Work Together
Lupus treatment is rarely a single medication. A typical regimen for someone with mild disease might be hydroxychloroquine plus an NSAID as needed. Moderate disease often adds a low dose of prednisone and possibly an immunosuppressant or biologic. Severe disease, particularly with kidney involvement, usually means hydroxychloroquine plus an immunosuppressant like mycophenolate, low-dose prednisone, and potentially voclosporin or a biologic.
The overarching trend in lupus care is toward using less prednisone and more targeted therapies. Steroid-sparing strategies, where biologics and immunosuppressants allow patients to taper off steroids faster, have become a central goal. This shift matters because while steroids control inflammation quickly, their long-term side effects can cause as much damage as the disease itself.